Levin Mark J's Form 4 filing
Jounce Therapeutics, Inc.JNCE · filed Nov 16, 2021
- Accession no.
- 0000899243-21-044916
- Filed
- Nov 16, 2021, 7:57 PM ET
- Trade date
- Nov 12, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $15.9M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Levin Mark JCIK 0001180428 | 10% Owner |
| Tepper Robert ICIK 0001192595 | 10% Owner |
| Starr Kevin PCIK 0001192603 | 10% Owner |
| Third Rock Ventures III, L.P.CIK 0001569705 | 10% Owner |
| TRV GP III, LLCCIK 0001637299 | 10% Owner |
| Third Rock Ventures GP III, L.P.CIK 0001637300 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2021 | Common Stock | SSaleDisposed | −1,900,000 | $8.38F1 | −$15,922,000 | 1,148,780 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.